Ch Biotech Ser (08037) announced that its indirectly non-wholly-owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., presented the results of Phase I clinical trial of LY007 cell injection (a new autologous chimeric antigen receptor T cell therapy product targeting CD20) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma (B-NHL) in the poster format at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

It is reported that diffuse large B-cell lymphoma (DLBCL) is a common subtype of B-cell non-Hodgkin's lymphoma, and most patients can be cured through standard immunotherapy. However, about 40% of patients still face the dilemma of relapse and refractory after first-line treatment. The purpose of the Phase I trial was to evaluate the safety and tolerability of LY007 cell injection in treating patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. The results of Phase I trial showed that LY007 cell injection had good tolerance at a dose level of up to 5.0 x 106 cells/kg and demonstrated a good dose-response relationship for treating relapsed and refractory B-cell non-Hodgkin's lymphoma. LY007 cell injection is expected to provide a new treatment option for patients with diffuse large B-cell lymphoma.

As of December 25, 2023, 9 patients had received a single dose of LY007 cell injection for 3 levels of treatment. The median follow-up was 5.09 months (range 0.92 to 18.10 months). 89% (8/9) of patients had extranodal involvement, 78% (7/9) had an International Prognostic Index (IPI) score ≥2. 44% (4/9) had a maximum tumor length ≥5 cm, and two patients had a maximum tumor length >8 cm.